Investing.com - AnaptysBio (NASDAQ:ANAB) reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
AnaptysBio announced earnings per share of $-1.18 on revenue of $1.29M. Analysts polled by Investing.com anticipated EPS of $-0.65 on revenue of $13.43M.
AnaptysBio shares are down 48.09% from the beginning of the year, still down 20.94% from its 52 week high of $37.40 set on December 23, 2021.
AnaptysBio follows other major Healthcare sector earnings this month
AnaptysBio's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar